MotherToBaby

Medications and More during pregnancy and breastfeeding

Search

866.626.6847

Tildrakizumab (Ilumya®)

Selected References:

  • English language version of Summary of Product Characteristics for Ilumetri (tildrakizumab) Accessed: https://www.ema.europa.eu/en/medicines/human/EPAR/ilumetri#product-information-section.
  • Gisondi P, et al. 2022. Italian adaptation of EuroGuiDerm guideline on the systemic treatment of chronic plaque psoriasis. Ital J Dermatol Venerol. 157(Suppl. 1 to No. 1):1-78.
  • Haycraft K, , et al. 2020. Outcomes of pregnancies from the tildrakizumab phase I–III clinical development programme. Br J Dermatol, 183: 184-186.
  • Iluyma® Prescribing Information. Available online at https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761067s000lbl.pdf. Accessed on May 1, 2023.
  • Owczarek W, et al. 2020. The use of biological drugs in psoriasis patients prior to pregnancy, during pregnancy and lactation: a review of current clinical guidelines. Postepy Dermatol Alergol. ;37(6):821-830.
  • Smith C, , et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. Br. J. Dermatol., 183: 628-637.
  • Yeung J, , et al. 2020. Management of Plaque Psoriasis With Biologic Therapies in Women of Child-Bearing Potential Consensus Paper. J Cutan Med Surg. 24(1_suppl):3S-14S.

This website is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $6,000,000 with zero percentage financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by, HRSA, HHS, or the U.S. Government.